Why Does the Future of Genetic Medicines Rely on LNP Targeting Strategies?

While the COVID-19 pandemic proved that LNPs can safely deliver mRNA for vaccine applicatios, the next generation of RNA medicines require precision delivery to extra-hepatic organs. This article explores how industry leaders are using AI and innovative lipid engineering to bypass the liver and deliver RNA therapeutics directly to the lungs, heart, and immune system, transforming LNPs into a programmable platform for chronic and rare diseases.

Read the full article here